

APA 2005

## AMERICAN PSYCHIATRIC ASSOCIATION CONTINUING MEDICAL EDUCATION POLICY ON FULL DISCLOSURE

The American Psychiatric Association requires disclosure, by presenters at CME activities, of any significant financial or other affiliation with commercial organization(s) regulated by the Food and Drug Administration, which may have a direct or indirect interest in the subject matter of the scientific program. A "financial interest" may include, but is not limited to, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An "affiliation" may include, holding a position on an advisory committee or some other role or benefit to a supporting organization.

Under the ACCME Standards for Commercial Support that were in effect when the 2005 Annual Meeting was planned, the existence of such relationships does not necessarily constitute a conflict of interest; but the prospective audience must be informed of the presenter's affiliation with every commercial supporter by an acknowledgement in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide or overhead is required if audiovisual equipment is used for the presentation). This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgments about the presentation. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose.

The list of presenters below have indicated that either they or an immediate family member has a significant interest or other affiliation with a commercial supporter of this meeting and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial services(s). The presenter's name and the company's name are listed, along with the page number the presenter appears on in this *Program Book*. The nature of the presenter's relationship with the disclosed company is indicated by the following code: consultant or advisory board<sup>1</sup>, full-time employment<sup>2</sup>, research/grant support<sup>3</sup>, speakers' bureau<sup>4</sup>, stock or other financial options<sup>5</sup>, other financial or business relationships<sup>6</sup>. If a number has not been assigned, the presenter has not disclosed the relationship to the company.

The second list of presenters, beginning on page XXXVI, have indicated neither they nor an immediate family member has any significant relationship to disclose. Voting member of the Board of Trustees, Assembly officers, and member of the Scientific Program Committee cannot receive honoraria or travel reimbursement for participating in Industry-Supported Symposia.

Presenter	Manufacturer(s)	Program Page #
Gene G. Abel, M.D.	Abel Screening, Inc. <sup>6</sup> ; Institute for Child Molestation Research and Prevention <sup>6</sup>	41
Donald E. Addington, M.D.	Eli Lilly and Company <sup>3</sup>	71
Marilyn Ader, Ph.D.	Janssen Pharmaceutica Products, LP. <sup>1,3</sup>	7
Nassima Ait-Daoud, M.D.	Ortho McNeil Pharmaceutical Inc. <sup>1</sup>	31, 56
Hagop S. Akiskal, M.D.	GlaxoSmithKline <sup>4</sup> ; Abbott Laboratories, Inc. <sup>4</sup> ; Eli Lilly and Company <sup>4</sup> ; Sanofi-Synthelabo Pharmaceuticals, Inc. <sup>4</sup> ; Bristol-Myers Squibb <sup>4</sup> ; Pfizer Inc. <sup>4</sup> ; AstraZeneca Pharmaceuticals <sup>4</sup> ; Janssen Pharmaceutica Products, LP. <sup>4</sup>	28
George S. Alexopoulos, M.D.	Forest Pharmaceuticals, Inc. <sup>1,3,4</sup> ; Cephalon Inc. <sup>3,4</sup> ; Janssen Pharmaceutica Products, LP. <sup>4</sup> ; Pfizer Inc. <sup>4</sup> ; Lilly Research Laboratories, a division of Eli Lilly and Company <sup>4</sup> ; Bristol-Myers Squibb <sup>4</sup> ; Meyers <sup>4</sup> ; GlaxoSmithKline <sup>4</sup>	6, 11
Jon G. Allen, Ph.D.	American Psychiatric Publishing, Inc. <sup>6</sup>	20
Michael H. Allen, M.D.	Abbott Laboratories, Inc. <sup>1,3,4</sup> ; Janssen Pharmaceutica Products, LP. <sup>1,3,4</sup> ; Lilly Research Laboratories, a division of Eli Lilly and Company <sup>1,3,4</sup> ; GlaxoSmithKline <sup>1,4</sup> ; Bristol-Myers Squibb <sup>1,3</sup> ; Pfizer Inc. <sup>1,4</sup> ; Novartis Pharmaceuticals Corporation <sup>3</sup> ; AstraZeneca Pharmaceuticals <sup>1,4</sup> ; Alexza <sup>1</sup>	12
Jonathan E. Alpert, M.D.	Organon Pharmaceuticals Inc. <sup>3,4</sup> ; Pharmanite <sup>3</sup> ; Eli Lilly and Company <sup>3</sup> ; Forest Pharmaceuticals, Inc. <sup>3</sup> ; Aspect Medical Systems, Inc. <sup>3</sup> ; Pfizer Inc. <sup>3</sup>	4
Sonia Ancoli-Israel, Ph.D.	King Pharmaceuticals <sup>4</sup> ; Takeda Pharmaceuticals <sup>4,1</sup> ; Neurocrine Biosciences Inc. <sup>1</sup> ; Sepracor Inc. <sup>1</sup>	9, 36
Allan A. Anderson, M.D.	Pfizer Inc. <sup>4</sup> ; Novartis Pharmaceuticals Corporation <sup>4</sup> ; Janssen Pharmaceutica Products, LP. <sup>4</sup> ; Forest Pharmaceuticals, Inc. <sup>4</sup>	49
Raymond F. Anton, Jr., M.D.	Bristol-Myers Squibb <sup>1,3</sup> ; Ortho McNeil Pharmaceutical Inc. <sup>1,3,4</sup> ; Alkermes Pharmaceuticals <sup>1</sup> ; Pfizer Inc. <sup>1,3</sup>	31, 62
Jose C. Appolinario, M.D.	Janssen Pharmaceutica Products, LP. <sup>3</sup> ; Abbott Laboratories, Inc. <sup>3</sup>	59
Michael R. Arambula, M.D.	Pfizer Inc. <sup>4</sup> ; AstraZeneca Pharmaceuticals <sup>4</sup>	35
Kimberly A. Arlinghaus, M.D.	UCB Pharmaceuticals <sup>1</sup> ; Bristol-Myers Squibb <sup>3</sup> ; Abbott Laboratories, Inc. <sup>3</sup> ; Pfizer Inc. <sup>3,4</sup> ; Forest Pharmaceuticals, Inc. <sup>3,4</sup> ; Wyeth Pharmaceuticals <sup>3,4</sup> ; AstraZeneca Pharmaceuticals <sup>3,4</sup> ; Janssen Pharmaceutica Products, LP. <sup>3,4</sup> ; Lilly Research Laboratories, a division of Eli Lilly and Company <sup>1,3,4</sup>	49
Scott C. Armstrong, M.D.	Pfizer Inc. <sup>4</sup> ; Lilly Research Laboratories, a division of Eli Lilly and Company <sup>4</sup> ; Janssen Pharmaceutica Products, LP. <sup>4</sup> ; Forest Pharmaceuticals, Inc. <sup>4</sup>	41



## DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Scott J. Crow, M.D.	Eli Lilly and Company <sup>3</sup> ; Ortho McNeil Pharmaceutical Inc. <sup>1,3</sup> ; Pfizer Inc. <sup>4</sup> ; GlaxoSmithKline <sup>3</sup>	6
Jeffrey L. Cummings, M.D.	Pfizer Inc. <sup>1,4</sup> ; Eisai, Inc. <sup>1,4</sup> ; Janssen Pharmaceutica Products, LP <sup>1,3,4</sup> ; Novartis Pharmaceuticals Corporation <sup>1,4</sup> ; Praecis Pharmaceuticals <sup>1</sup> ; Lilly Research Laboratories, a division of Eli Lilly and Company <sup>1</sup> ; AstraZeneca Pharmaceuticals <sup>1</sup> ; Forest Pharmaceuticals, Inc. <sup>1,3,4,6</sup> ; Bristol-Myers Squibb <sup>1</sup> ; Roche Laboratories, a member of the Roche Group <sup>1</sup> ; Aventis Pharmaceuticals <sup>1</sup> ; Cortex Pharmaceuticals Pharmaceutical <sup>3</sup> ; Lundbeck <sup>1</sup> ; Myriad Genetics, Inc. <sup>1</sup> ; Ono Pharmaceuticals <sup>1</sup>	9, 13, 39
Cheryl Davenport	Merrill Lynch <sup>5,6</sup>	43
Jonathan S. Davine, M.D.	Eli Lilly and Company <sup>1,4</sup> ; GlaxoSmithKline <sup>1,4</sup> ; Janssen Pharmaceutica Products, LP <sup>1,4</sup> ; Lundbeck <sup>1,4</sup> ; Organon Pharmaceuticals Inc. <sup>1,4</sup> ; Pfizer Inc. <sup>1,4</sup> ; Wyeth Pharmaceuticals <sup>1,4</sup>	30, 86
Lori L. Davis, M.D.	Ortho McNeil Pharmaceutical Inc. <sup>3</sup> ; Abbott Laboratories, Inc. <sup>3,4</sup> ; Bristol-Myers Squibb <sup>3</sup> ; Elan Pharmaceuticals <sup>3</sup> ; Forest Pharmaceuticals, Inc. <sup>3</sup>	3
Deborah Deas, M.D.	Pfizer Inc. <sup>3</sup> ; Eli Lilly and Company <sup>4</sup>	3, 36
Charles DeBattista, M.D.	Corcept Therapeutics <sup>1,5</sup> ; GlaxoSmithKline <sup>3,4</sup> ; Wyeth Pharmaceuticals <sup>3,4</sup> ; Abbott Laboratories, Inc. <sup>3,4</sup> ; Lilly Research Laboratories, a division of Eli Lilly and Company <sup>3,4</sup> ; Pfizer Inc. <sup>3,4</sup> ; Cephalon Inc. <sup>3,4</sup>	4
Melissa P. DelBello, M.D.	Abbott Laboratories, Inc. <sup>3,4</sup> ; AstraZeneca Pharmaceuticals <sup>3,4</sup> ; Eli Lilly and Company <sup>1,3,4</sup> ; Ortho McNeil Pharmaceutical Inc. <sup>1,3,4</sup> ; Janssen Pharmaceutica Products, LP <sup>3,4</sup> ; Pfizer Inc. <sup>1,3,4</sup> ; GlaxoSmithKline <sup>4</sup> ; Bristol-Myers Squibb <sup>1,4</sup> ; Shire Ridgewood Pharmaceuticals <sup>1</sup>	3, 35, 77
Pedro L. Delgado, M.D.	National Institute of Mental Health <sup>3</sup> ; Eli Lilly and Company <sup>1,3,4</sup> ; GlaxoSmithKline <sup>1,3,4</sup> ; Organon Pharmaceuticals Inc. <sup>1,3,4</sup> ; Wyeth Pharmaceuticals <sup>1,3,4</sup> ; Forest Pharmaceuticals, Inc. <sup>3</sup>	55, 64
Diana L. Dell, M.D.	Eli Lilly and Company <sup>1,3,4</sup> ; Pfizer Inc. <sup>1,3,4</sup> ; Berlex Laboratories, Inc. <sup>3,4</sup> ; GlaxoSmithKline <sup>3,4</sup> ; Wyeth Pharmaceuticals <sup>4</sup> ; TAP Pharmaceuticals Product, Inc. <sup>4</sup>	66
Mark Demitrack, M.D.	Neuronetics, Inc. <sup>2,5</sup> ; Wyeth Pharmaceuticals <sup>5</sup> ; Eli Lilly and Company <sup>5</sup>	84
Davangere P. Devanand, M.D.	Pfizer Inc. <sup>3</sup> ; Wyeth Pharmaceuticals <sup>3</sup> ; Janssen Pharmaceutica Products, LP <sup>1</sup> ; Organon Pharmaceuticals Inc. <sup>1</sup>	2
Michael Devin, M.D.	Eli Lilly and Company <sup>3</sup>	1
Mantosh J. Dewan, M.D.	Pfizer Inc. <sup>4</sup> ; AstraZeneca Pharmaceuticals <sup>4</sup> ; GlaxoSmithKline <sup>4</sup> ; Lilly Research Laboratories, a division of Eli Lilly and Company <sup>3</sup> ; Janssen Pharmaceutica Products, LP <sup>3</sup>	3, 18, 54, 79
Andrea F. DiMartini, M.D.	National Institute of Alcohol Abuse and Alcoholism (NIAAA) <sup>3</sup>	40
Lisa B. Dixon, M.D.	Bristol-Myers Squibb <sup>3,5</sup> ; Pfizer Inc. <sup>3,5</sup> ; Lilly Research Laboratories, a division of Eli Lilly and Company <sup>3</sup> ; Janssen Pharmaceutica Products, LP <sup>3</sup>	29, 55, 84, 93
John P. Docherty, M.D.	Nutrition 21, Inc. <sup>3</sup> ; Bristol-Myers Squibb <sup>1,3,4</sup> ; Janssen Pharmaceutica Products, LP <sup>1,4</sup> ; Forest Pharmaceuticals, Inc. <sup>3,4</sup> ; AstraZeneca Pharmaceuticals <sup>3</sup> ; Abbott Laboratories, Inc. <sup>3</sup> ; Novartis Pharmaceuticals Corporation <sup>3</sup> ; GlaxoSmithKline <sup>3</sup> ; Eli Lilly and Company <sup>3</sup>	31, 70
Manfred Doepfner, M.D.	Eli Lilly and Company <sup>6</sup>	34
Martin Dossenbach, M.D.	Eli Lilly and Company <sup>2</sup>	89
Alysa Doyle, Ph.D.	Eli Lilly and Company <sup>1</sup> ; McNeil Pharmaceuticals <sup>4</sup>	57
Robert Drake, M.D.	Johnson and Johnson PRD <sup>3</sup>	29
Douglas A. Drossman, M.D.	Novartis Pharmaceuticals Corporation <sup>1,3</sup> ; Solvay Pharmaceuticals, Inc. <sup>1,3,4</sup> ; GlaxoSmithKline <sup>1</sup>	53
Roxanne Dryden-Edwards, M.D.	Eli Lilly and Company <sup>3</sup>	18
Sanjay Dube, M.D.	Eli Lilly and Company <sup>2</sup>	28, 67
David W. Dunn, M.D.	Eli Lilly and Company <sup>1,3,4</sup> ; Shire Ridgewood Pharmaceuticals <sup>3</sup> ; AstraZeneca Pharmaceuticals <sup>3</sup> ; The National Institute of Neurological Disorders and Stroke (NINDS) <sup>3</sup> ; O'Neil <sup>4</sup> ; UCB Pharmaceuticals <sup>4</sup>	95
David L. Dunner, M.D.	Eli Lilly and Company <sup>1,3,4</sup> ; Pfizer Inc. <sup>1,3,4</sup> ; GlaxoSmithKline <sup>1,3,4</sup> ; Wyeth Pharmaceuticals <sup>1,3,4</sup> ; Bristol-Myers Squibb <sup>1,4</sup> ; Organon Pharmaceuticals Inc. <sup>4</sup> ; Forest Pharmaceuticals, Inc. <sup>4</sup> ; Cyberonics, Inc. <sup>3</sup> ; Merck & Co., Inc. <sup>3</sup> ; Cypress Bioscience, Inc. <sup>1</sup> ; Corcept Therapeutics <sup>1</sup> ; Janssen Pharmaceutica Products, LP <sup>1,3</sup> ; Novartis Pharmaceuticals Corporation <sup>1</sup> ; Shire Ridgewood Pharmaceuticals <sup>1</sup> ; Somerset Pharmaceuticals Inc. <sup>1</sup> ; Otsuka America Pharmaceutical, Inc. <sup>1</sup>	37
Helen L. Egger, M.D.	Pfizer Inc. <sup>3</sup>	19
Omar Elhaj, M.D.	AstraZeneca Pharmaceuticals <sup>1</sup> ; Abbott Laboratories, Inc. <sup>1</sup> ; Pfizer Inc. <sup>1</sup>	25, 67
James M. Ellison, M.D.	GlaxoSmithKline <sup>3,4</sup> ; Forest Pharmaceuticals, Inc. <sup>4</sup> ; Pfizer Inc. <sup>4</sup> ; Wyeth Pharmaceuticals <sup>4</sup> ; Bristol-Myers Squibb <sup>4</sup>	75



## DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Graham J. Emslie, M.D.	Eli Lilly and Company <sup>1,3</sup> ; Organon Pharmaceuticals Inc. <sup>3</sup> ; GlaxoSmithKline <sup>1</sup> ; Forest Pharmaceuticals, Inc. <sup>1</sup> ; Pfizer Inc. <sup>1</sup> ; Wyeth Pharmaceuticals <sup>1</sup> ; Ortho McNeil Pharmaceutical Inc. <sup>4</sup>	42, 66
Mary Jane England, M.D.	American Healthways, Inc. <sup>3</sup> ; US Behavioral Health <sup>6</sup>	43, 83
Milton K. Erman, M.D.	Cephalon Inc. <sup>1,6,4,3,5</sup> ; Elan Pharmaceuticals <sup>1,3,6</sup> ; King Pharmaceutical <sup>1,3,4,6</sup> ; Neurocrine Biosciences Inc. <sup>1,3,6</sup> ; Orphan <sup>1,3,6</sup> ; Sanofi-Synthelabo Pharmaceuticals, Inc. <sup>1,3,6</sup> ; Takeda Pharmaceuticals <sup>1,6</sup> ; Janssen Pharmaceutica Products, LP <sup>1</sup> ; Mallinckrodt, Inc. <sup>1,3,6</sup> ; Somaxon Pharmaceuticals <sup>1</sup> ; Aventis Pharmaceuticals <sup>3</sup> ; Pharmacia <sup>3</sup> ; Pfizer Inc. <sup>3,5</sup> ; Res-Med, Inc. <sup>3</sup> ; Merck & Co., Inc. <sup>3,5</sup> ; Sepracor Inc. <sup>5</sup> ; Forest Pharmaceuticals, Inc. <sup>4,5</sup>	9
Javier I. Escobar, M.D.	Eli Lilly and Company <sup>1,4</sup> ; Pfizer Inc. <sup>1,4,5</sup> ; Bristol-Myers Squibb <sup>1,4,5</sup> ; Otsuka America Pharmaceutical, Inc. <sup>1,4</sup> ; Johnson and Johnson PRD <sup>5</sup> ; Wyeth Pharmaceuticals <sup>1</sup>	18, 59, 64
Raymond A. Faber, M.D.	Forest Pharmaceuticals, Inc. <sup>4</sup> ; Bristol-Myers Squibb <sup>4</sup> ; Janssen Pharmaceutica Products, LP <sup>4</sup> ; Pfizer Inc. <sup>4</sup>	1
Warachal E. Faison, M.D.	National Institute on Health <sup>3</sup> ; Janssen Pharmaceutica Products, LP <sup>3,4</sup> ; Organon Pharmaceuticals Inc. <sup>3</sup> ; Eli Lilly and Company <sup>4</sup> ; Pfizer Inc. <sup>4</sup> ; Eisai Inc. <sup>4</sup> ; Bristol-Myers Squibb <sup>4</sup> ; Otsuka America Pharmaceutical <sup>4</sup> ; Forest Pharmaceuticals, Inc. <sup>4</sup> ; GlaxoSmithKline <sup>2,5</sup>	9, 43, 47
Bruno Falissard, M.D.	Eli Lilly and Company <sup>6</sup>	34
Stephen V. Faraone, Ph.D.	Noven Pharmaceutical <sup>1</sup> ; Ortho McNeil Pharmaceutical Inc. <sup>1,3,4</sup> ; Shire Ridgewood Pharmaceuticals <sup>1,3,4</sup> ; Eli Lilly and Company <sup>1,3,4</sup> ; National Institute of Mental Health <sup>3</sup> ; National Institute of Child Health and Human Development <sup>3</sup> ; National Institute of Neurological Diseases and Stroke <sup>3</sup>	12, 62, 80
Douglas E. Faries, Ph.D.	Eli Lilly and Company <sup>2</sup>	25
Maurizio Fava, M.D.	Loxex Pharmaceuticals <sup>3</sup> ; Lichtwer Pharma GmbH <sup>3</sup> ; Abbott Laboratories, Inc. and Compellis <sup>3,6</sup> ; Aspect Medical Systems, Inc. <sup>3,6</sup> ; AstraZeneca Pharmaceuticals <sup>3,6</sup> ; Bristol-Myers Squibb <sup>3,6</sup> ; Cephalon Inc. <sup>3,6</sup> ; Eli Lilly and Company <sup>3,6</sup> ; Forest Pharmaceuticals, Inc. <sup>3,6</sup> ; GlaxoSmithKline <sup>3,6</sup> ; Johnson and Johnson PRD <sup>3,6</sup> ; Novartis Pharmaceuticals Corporation <sup>3,6</sup> ; Organon Pharmaceuticals Inc. <sup>3,6</sup> ; Pharmavite <sup>3,6</sup> ; Pfizer Inc. <sup>3,6</sup> ; Roche Laboratories, a member of the Roche Group <sup>3,6</sup> ; Sanofi-Synthelabo Pharmaceuticals, Inc. <sup>3,6</sup> ; Solvay Pharmaceuticals, Inc. <sup>3,6</sup> ; Wyeth Pharmaceuticals <sup>3,6</sup> ; Bayer AG Corporation, Pharmaceutical Division <sup>6</sup> ; Janssen Pharmaceutica Products, LP <sup>6</sup> ; Knoll Pharmaceuticals <sup>6</sup> ; Lundbeck <sup>6</sup> ; Cypress Bioscience, Inc. <sup>6</sup> ; Somerset Pharmaceuticals Inc. <sup>6</sup>	4, 55, 89
Francisco Fernandez, M.D.	Wyeth Pharmaceuticals <sup>1,4</sup> ; Forest Pharmaceuticals, Inc. <sup>1,4</sup> ; Pfizer Inc. <sup>1,4</sup> ; Eli Lilly and Company <sup>4</sup>	20, 43, 51
Robert L. Findling, M.D.	Abbott Laboratories, Inc. <sup>1,3,4</sup> ; AstraZeneca Pharmaceuticals <sup>1,3,4</sup> ; Best Practices <sup>1</sup> ; Bristol-Myers Squibb <sup>1,3,4</sup> ; Celltech-Medeva <sup>1,3</sup> ; Forest Pharmaceuticals, Inc. <sup>1,3</sup> ; GlaxoSmithKline <sup>1,3,4</sup> ; Johnson and Johnson PRD <sup>1,3,4</sup> ; Layton Biosciences, Inc. <sup>3</sup> ; Lilly Research Laboratories, a division of Eli Lilly and Company <sup>1,3,4</sup> ; Nature's Herbs <sup>3</sup> ; Novartis Pharmaceuticals Corporation <sup>1,3</sup> ; Noven Pharmaceutical <sup>1</sup> ; Organon Pharmaceuticals Inc. <sup>3</sup> ; Otsuka America Pharmaceutical <sup>1,3,4</sup> ; PharmaStar, LLC <sup>1</sup> ; Pharmaceutical Product Development, Inc. (PPD) <sup>1</sup> ; Pfizer Inc. <sup>1,3</sup> ; Shire Ridgewood Pharmaceuticals <sup>1,3,4</sup> ; Solvay Pharmaceuticals, Inc. <sup>3</sup> ; Somerset Pharmaceuticals Inc. <sup>1,3</sup> ; Wyeth Pharmaceuticals <sup>1,3,4</sup>	2, 25
Naomi Fineberg, M.A.	AstraZeneca Pharmaceuticals <sup>3</sup> ; Janssen Pharmaceutica Products, LP <sup>3</sup> ; Lundbeck <sup>1</sup>	79
David A. Fishbain, M.D.	Eli Lilly and Company <sup>1</sup>	4
Sebern F. Fisher, M.A.	EEG Spectrum International <sup>1,4,5</sup>	74
James N. Flack, M.D.	Janssen Pharmaceutica Products, LP <sup>4</sup>	19
Lois T. Flaherty, M.D.	Merck & Co., Inc. <sup>6,5</sup> ; Pfizer Inc. <sup>5</sup>	20, 85
Marshal Folstein, M.D.	CNS Vital Signs LLC	68
Brent P. Forester, M.D.	Eli Lilly and Company <sup>3,4</sup> ; Wyeth Pharmaceuticals <sup>4</sup> ; Novartis Pharmaceuticals Corporation <sup>4</sup> ; Janssen Pharmaceutica Products, LP <sup>4</sup> ; Abbott Laboratories, Inc. <sup>3,4</sup> ; AstraZeneca Pharmaceuticals <sup>4</sup> ; Pfizer Inc. <sup>3,4</sup>	75
Paul T. Francis, Ph.D.	Pfizer Inc./Eisai Inc. <sup>4</sup> ; Lundbeck <sup>4</sup> ; Forest Pharmaceuticals, Inc. <sup>4</sup>	9
Ellen Frank, Ph.D.	Pfizer Inc. <sup>1</sup> ; Pfizer Italiana <sup>1</sup> ; Eli Lilly and Company <sup>1</sup> ; Forest Pharmaceuticals, Inc. <sup>3</sup>	4
Robert Freedman, M.D.	Abbott Laboratories, Inc. <sup>3</sup> ; The Dept. of Veteran Affairs <sup>6</sup>	41
Matthew Friedman, M.D.	Shire Ridgewood Pharmaceuticals <sup>1</sup> ; GlaxoSmithKline <sup>4</sup> ; Ortho McNeil Pharmaceutical Inc. <sup>4</sup> ; AstraZeneca Pharmaceuticals <sup>4</sup>	19, 34, 95
Lara R. Fuchs, M.D.	GlaxoSmithKline <sup>6</sup>	66
Manuel Garcia, M.D.	Pfizer Inc. <sup>2,5</sup>	45
Bradley N. Gaynes, M.D.	Pfizer Inc. <sup>1</sup>	58
Osvaldo Gaytan, Jr., M.D.	Pfizer Inc. <sup>4</sup> ; AstraZeneca Pharmaceuticals <sup>4</sup> ; Janssen Pharmaceutica Products, LP <sup>4</sup>	79



# DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Alan J. Gelenberg, M.D.	Pfizer Inc. <sup>1,3,4</sup> ; Wyeth Pharmaceuticals <sup>1,3,4</sup> ; Cyberonics, Inc. <sup>1,4</sup> ; Eli Lilly and Company <sup>1</sup> ; Vela Pharmaceuticals <sup>1</sup> ; Best Practice <sup>1</sup> ; Bristol-Myers Squibb <sup>1</sup> ; AstraZeneca Pharmaceuticals <sup>1</sup> ; GlaxoSmithKline <sup>1</sup> ; Roche Laboratories, a member of the Roche Group <sup>1</sup> ; ZARS <sup>1</sup> ; Express Scripts <sup>1</sup>	22
Mark S. George, M.D.	Neotonus, Inc. (now Neuronetics Inc.) <sup>1,3</sup> ; Janssen Pharmaceutica Products, LP <sup>3,4</sup> ; Lilly Research Laboratories, a division of Eli Lilly and Company <sup>3,4</sup> ; GlaxoSmithKline <sup>3,4</sup> ; Solvay/Duphar <sup>3,4</sup> ; Parke Davis <sup>3,4</sup> ; Cortex Pharmaceuticals <sup>3</sup> ; Aventis Pharmaceuticals <sup>1</sup> ; DarPharma, Inc. <sup>3</sup> ; Picker International (now Phillips) <sup>3,4</sup> ; Dantee (Medtronic) <sup>3</sup> ; Cyberonics, Inc. <sup>1,3,4</sup> ; Dupont Pharma <sup>3</sup> ; Medipysics/Amersham <sup>3,4</sup> ; Cephos Corp. <sup>1,3</sup>	6, 15, 47
Anna M. Georgiopoulos, M.D.	GlaxoSmithKline <sup>3</sup>	82
S. Nassir Ghaemi, M.D.	Janssen Pharmaceutica Products, LP <sup>1,3,6</sup> ; AstraZeneca Pharmaceuticals <sup>1,3,6</sup> ; Novartis Pharmaceuticals Corporation <sup>3</sup> ; Abbott Laboratories, Inc. <sup>3,6</sup> ; Elan Pharmaceuticals <sup>3</sup> ; GlaxoSmithKline <sup>1,6</sup> ; Forest Pharmaceuticals, Inc. <sup>6</sup> ; Eli Lilly and Company <sup>6</sup>	33, 36, 56, 77
Leslie H. Gise, M.D.	Medco Health <sup>1</sup>	14, 30
Alexander H. Glassman, M.D.	Pfizer Inc. <sup>1,4</sup> ; GlaxoSmithKline <sup>1,4</sup> ; Eli Lilly and Company <sup>1</sup> ; AstraZeneca Pharmaceuticals <sup>1,4</sup> ; Ono Pharma <sup>1</sup>	20
Ira D. Glick, M.D.	Janssen Pharmaceutica Products, LP <sup>1,3,4</sup> ; Lilly Research Laboratories, a division of Eli Lilly and Company <sup>1,3,4</sup> ; Pfizer Inc. <sup>1,3,4</sup> ; Bristol-Myers Squibb <sup>1,3,4</sup> ; AstraZeneca Pharmaceuticals <sup>1,3,4</sup>	15, 33, 59, 82
Donald C. Goff, M.D.	Cortex Pharmaceuticals <sup>3</sup> ; Eli Lilly and Company <sup>1,6</sup> ; Janssen Pharmaceutica Products, LP <sup>1,3,6</sup> ; AstraZeneca Pharmaceuticals <sup>1,6</sup> ; Pfizer Inc. <sup>1,6</sup> ; Bristol-Myers Squibb <sup>1,6</sup> ; Cephalon Inc. <sup>3</sup> ; GlaxoSmithKline <sup>3</sup> ; Organon Pharmaceuticals Inc. <sup>3</sup>	7
Robert M. Goisman, M.D.	Bristol-Myers Squibb <sup>1</sup> ; AstraZeneca Pharmaceuticals <sup>4</sup> ; Pfizer Inc. <sup>4</sup>	64
Joseph F. Goldberg, M.D.	Abbott Laboratories, Inc. <sup>1,3,4</sup> ; AstraZeneca Pharmaceuticals <sup>1,3,4</sup> ; Bristol-Myers Squibb <sup>1,3,4</sup> ; Eli Lilly and Company <sup>1,3,4</sup> ; GlaxoSmithKline <sup>1,3,4</sup> ; Johnson and Johnson PRD <sup>1</sup> ; Novartis Pharmaceuticals Corporation <sup>1</sup> ; Ortho McNeil Pharmaceutical Inc. <sup>1</sup> ; Organon Pharmaceuticals Inc. <sup>1</sup> ; Pfizer Inc. <sup>1,4</sup> ; UCB Pharmaceuticals <sup>1</sup>	23, 77
Robert N. Golden, M.D.	Bristol-Myers Squibb <sup>1</sup> ; Duke Clinical Research Institute (DCRI) <sup>1</sup> ; Forest Pharmaceuticals, Inc. <sup>3</sup> ; GlaxoSmithKline <sup>1</sup> ; Janssen Pharmaceutica Products, LP <sup>1</sup> ; National Institute of Mental Health <sup>3</sup> ; Organon Pharmaceuticals Inc. <sup>3,4</sup> ; Ovation Pharmaceuticals <sup>1</sup> ; Pfizer Inc. <sup>1,3</sup> ; Wyeth Pharmaceuticals <sup>1</sup>	69
Stephen M. Goldfinger, M.D.	Bristol-Myers Squibb <sup>1</sup> ; Mallinckrodt Pharmaceuticals <sup>1,3,4</sup> ; AstraZeneca Pharmaceuticals <sup>1,3,4</sup> ; Pfizer Inc. <sup>1,3,4</sup> ; Janssen Pharmaceutica Products, LP <sup>1,4,5</sup> ; IVAX Pharmaceuticals, Inc. <sup>1,4,5</sup>	45, 68, 74, 92
Morris B. Goldman, M.D.	Bristol-Myers Squibb <sup>1</sup>	27
Andres Gomez-Caminero, Ph.D.	GlaxoSmithKline <sup>5</sup> ; Bristol-Myers Squibb <sup>2</sup>	54
Karl Goodkin, M.D.	GlaxoSmithKline <sup>3</sup> ; Merck & Co., Inc. <sup>1,4</sup> ; BI <sup>1,4</sup> ; Advance ImmvriT, Inc. <sup>6</sup> ; American Society for Microbiology <sup>6</sup>	43
David Goodman, M.D.	Forest Pharmaceuticals, Inc. <sup>1,3,4</sup> ; Shire Ridgewood Pharmaceuticals <sup>1,3,4</sup> ; Ortho McNeil Pharmaceutical Inc. <sup>1,3,4</sup> ; GlaxoSmithKline <sup>1,4</sup> ; Pfizer Inc. <sup>5</sup> ; Eli Lilly and Company <sup>4</sup> ; Wyeth Pharmaceuticals <sup>4</sup>	32
Marianne Goodman, M.D.	Forest Pharmaceuticals, Inc. <sup>3</sup>	33
Frederick K. Goodwin, M.D.	Solvay Pharmaceuticals, Inc. <sup>1,3,4</sup> ; GlaxoSmithKline <sup>1,3,4</sup> ; Pfizer Inc. <sup>1,3,4</sup> ; Lilly Research Laboratories, a division of Eli Lilly and Company <sup>1,3,4</sup> ; Bristol-Myers Squibb <sup>1,3,4</sup> ; Abbott Laboratories, Inc. <sup>3</sup> ; Forest Pharmaceuticals, Inc. <sup>3</sup> ; Sanofi-Synthelabo Pharmaceuticals, Inc. <sup>3</sup> ; Janssen Pharmaceutica Products, LP <sup>3,4</sup>	36, 56
Kevin F. Gray, M.D.	Novartis Pharmaceuticals Corporation <sup>4,1</sup> ; Lilly Research Laboratories, a division of Eli Lilly and Company <sup>4,1</sup> ; Pfizer Inc. <sup>4,1</sup> ; Janssen Pharmaceutica Products, LP <sup>4</sup> ; Bristol-Myers Squibb <sup>4,1</sup>	1
John F. Greden, M.D.	Eli Lilly and Company <sup>1</sup> ; Wyeth Pharmaceuticals <sup>1</sup> ; Merck & Co., Inc. <sup>1</sup> ; Cyberonics, Inc. <sup>1</sup> ; Neurocrine Biosciences Inc. <sup>1</sup> ; GlaxoSmithKline <sup>1</sup>	11, 20, 37, 41, 49, 84
Alan I. Green, M.D.	Bristol-Myers Squibb <sup>1,3,4</sup> ; Otsuka America Pharmaceutical, Inc. <sup>1,3,4</sup> ; Eli Lilly and Company <sup>1,3,4</sup> ; Janssen Pharmaceutica Products, LP <sup>1,3,4</sup> ; AstraZeneca Pharmaceuticals <sup>1,3,4</sup> ; Forest Pharmaceuticals, Inc. <sup>1,3</sup> ; Novartis Pharmaceuticals Corporation <sup>3</sup>	29, 36, 50
Melva I. Green, M.D.	Pfizer Inc. <sup>4</sup>	43
Benjamin D. Greenberg, M.D.	Medtronic, Inc. <sup>3,4</sup> ; Aspect Medical Systems, Inc. <sup>1</sup>	6, 90
Laurence L. Greenhill, M.D.	Novartis Pharmaceuticals Corporation <sup>3,1</sup> ; Eli Lilly and Company <sup>1,3,4</sup> ; Celltech Pharmaceuticals, Ltd. <sup>1,4</sup> ; Ortho McNeil Pharmaceutical Inc. <sup>1</sup> ; Janssen Pharmaceutica Products, LP <sup>1</sup>	23
Carl B. Greiner, M.D.	Janssen Pharmaceutica Products, LP <sup>4</sup>	43, 64
Dimitri E. Grigoriadis, Ph.D.	Neurocrine Biosciences Inc. <sup>2</sup>	32



## DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
David G. Kingdon, M.D.	Eli Lilly and Company <sup>6</sup> ; Bristol-Myers Squibb <sup>6</sup> ; AstraZeneca Pharmaceuticals <sup>6</sup> ; GlaxoSmithKline <sup>6</sup> ; Novartis Pharmaceuticals Corporation <sup>6</sup> ; Janssen Pharmaceutica Products, LP <sup>6</sup> ; Pfizer Inc. <sup>6</sup>	8, 92
Joel I. Kirson, M.D.	GlaxoSmithKline <sup>4</sup>	23, 71
Herbert D. Kleber, M.D.	Reckitt Benckiser Pharmaceuticals <sup>3</sup> ; Purdue Pharma L.P. <sup>1</sup>	15, 60, 80
Scott Kollins, Ph.D.	Ortho McNeil Pharmaceutical Inc. <sup>1,4</sup> ; Shire Ridgewood Pharmaceuticals <sup>1,3</sup> ; Celltech Pharmaceuticals, Ltd. <sup>3</sup> ; Lilly Research Laboratories, a division of Eli Lilly and Company <sup>3</sup>	11
George F. Koob, Ph.D.	Merck & Co., Inc./Lipha <sup>1</sup> ; Titan Pharmaceuticals <sup>1</sup> ; Addex Pharmaceuticals <sup>1</sup> ; Forest Pharmaceuticals, Inc. <sup>1</sup>	56, 62, 96
Lorin M. Koran, M.D.	Forest Pharmaceuticals, Inc. <sup>3,4</sup> ; Pfizer Inc. <sup>3,4</sup> ; AstraZeneca Pharmaceuticals <sup>3</sup> ; GlaxoSmithKline <sup>3</sup>	79
Susan G. Kornstein, M.D.	Pfizer Inc. <sup>1,3</sup> ; Bristol-Myers Squibb <sup>1,3</sup> ; Eli Lilly and Company <sup>1,3</sup> ; Merck & Co., Inc. <sup>3</sup> ; Forest Pharmaceuticals, Inc. <sup>3</sup> ; Wyeth Pharmaceuticals <sup>3,1</sup> ; Berlex Laboratories, Inc. <sup>3</sup> ; Sepracor Inc. <sup>3</sup> ; Novartis Pharmaceuticals Corporation <sup>3</sup> ; Warner-Chilcott <sup>1</sup> ; Biovail Laboratories Inc. <sup>3</sup>	13, 39, 66
Diana M. Koziupa, M.D.	Eli Lilly and Company <sup>3,4</sup> ; Bristol-Myers Squibb <sup>1,4</sup> ; Otsuka America Pharmaceutical <sup>4</sup> ; Forest Pharmaceuticals, Inc. <sup>4</sup> ; GlaxoSmithKline <sup>4</sup> ; Sanofi-Synthelabo Pharmaceuticals, Inc. <sup>4</sup> ; Wyeth Pharmaceuticals <sup>4</sup>	60
Henry R. Kranzler, M.A.	Alkermes Pharmaceuticals <sup>1</sup> ; Forest Pharmaceuticals, Inc. <sup>1</sup> ; Bristol-Myers Squibb <sup>1</sup> ; Ortho McNeil Pharmaceutical Inc. <sup>3</sup> ; Drug Abuse Sciences <sup>4</sup>	31
Christopher J. Kratochvil, M.D.	Eli Lilly and Company <sup>1,3,4</sup> ; Forest Pharmaceuticals, Inc. <sup>3</sup> ; Cephalon Inc. <sup>3</sup> ; GlaxoSmithKline <sup>3</sup> ; Ortho McNeil Pharmaceutical Inc. <sup>3,4</sup>	34, 62
John E. Kraus, Jr., M.D.	Bristol-Myers Squibb <sup>1,3,4</sup> ; Pfizer Inc. <sup>1,3,4</sup> ; Eli Lilly and Company <sup>1,3,4</sup> ; AstraZeneca Pharmaceuticals <sup>1,3,4</sup>	4
K. Ranga R. Krishnan, M.D.	GlaxoSmithKline <sup>1</sup> ; Pfizer Inc. <sup>1</sup> ; Eli Lilly and Company <sup>1</sup> ; Vela Pharmaceuticals <sup>1</sup> ; Lundbeck <sup>1</sup> ; Abbott Laboratories, Inc. <sup>1</sup> ; Amgen <sup>1</sup> ; Johnson and Johnson PRD <sup>1</sup> ; Merck & Co., Inc. <sup>1</sup> ; NPS Pharmaceuticals <sup>1</sup> ; Organon Pharmaceuticals Inc. <sup>1</sup> ; Otsuka America Pharmaceutical <sup>1</sup> ; Pfizer Inc. <sup>1</sup> ; Somerset Pharmaceuticals Inc. <sup>1</sup> ; Wyeth Pharmaceuticals <sup>1</sup> ; Synaptic <sup>1</sup>	2, 41, 62, 81
Kurt Kroenke, M.D.	AstraZeneca Pharmaceuticals <sup>1</sup> ; Wyeth Pharmaceuticals <sup>1,3</sup> ; Eli Lilly and Company <sup>1,3</sup> ; Pfizer Inc. <sup>1,3</sup>	25
Larry A. Kroutil, M.P.H.	Eli Lilly and Company <sup>3</sup>	90
John H. Krystal, M.D.	Organon Pharmaceuticals Inc. <sup>1</sup> ; Janssen Pharmaceutica Products, LP <sup>1</sup> ; Aventis Pharmaceuticals <sup>1</sup> ; GlaxoSmithKline <sup>1</sup> ; Pfizer Inc. <sup>1</sup> ; Eli Lilly and Company <sup>1</sup> ; Forest Pharmaceuticals, Inc. <sup>1</sup> ; Takeda Pharmaceuticals <sup>1</sup> ; Merz Pharmaceuticals <sup>1</sup> ; Centre de Recherche Pierre Fabre <sup>1</sup> ; UCB Pharmaceuticals <sup>1</sup> ; Sumitomo Pharmaceuticals America, Ltd. <sup>1</sup>	11, 29
Elisabeth J.S. Kunkel, M.D.	Pfizer Inc. <sup>4</sup> ; Intramed <sup>4</sup> ; Forest Pharmaceuticals, Inc. <sup>4</sup> ; Wyeth Pharmaceuticals <sup>4</sup>	40, 91, 96
David J. Kupfer, M.D.	Pfizer Inc. <sup>1</sup> ; Eli Lilly and Company <sup>1</sup> ; Forest Pharmaceuticals, Inc. <sup>1</sup> ; F. Hoffmann-La Roche, LTD. <sup>1</sup> ; Servier Amerique <sup>1</sup>	9, 20, 30
Raymond W. Lam, M.D.	Biovail Laboratories Inc. <sup>4</sup> ; Canadian Network for Mood and Anxiety Treatments <sup>4</sup> ; Eli Lilly and Company <sup>3,4</sup> ; GlaxoSmithKline <sup>3,4</sup> ; Litebook Company, Inc. <sup>4</sup> ; Lundbeck <sup>3,4</sup> ; Shire Ridgewood Pharmaceuticals <sup>4</sup> ; Wyeth Pharmaceuticals <sup>3,4</sup> ; AstraZeneca Pharmaceuticals <sup>3</sup> ; Canadian Institutes of Health Research <sup>3</sup> ; Janssen Pharmaceutica Products, LP <sup>3</sup> ; Merck & Co., Inc. <sup>3</sup> ; Roche Laboratories, a member of the Roche Group <sup>3</sup> ; Servier Canada <sup>3</sup> ; Vancouver Hospital Foundation <sup>3</sup>	61
Jeanne Landgraf, M.A.	Shire Ridgewood Pharmaceuticals <sup>3</sup>	32
Edward C. Lauterbach, M.D.	Bristol-Myers Squibb <sup>3</sup> ; Forest Pharmaceuticals, Inc. <sup>4</sup>	5, 48, 71, 89
Helen Lavretsky, M.D.	Forest Pharmaceuticals, Inc. <sup>3,4,1</sup> ; Janssen Pharmaceutica Products, LP <sup>4,1</sup> ; Pfizer Inc. <sup>4</sup> ; AstraZeneca Pharmaceuticals <sup>1,3</sup> ; Bristol-Myers Squibb <sup>1,3</sup>	62, 64
William Lawson, M.D.	Abbott Laboratories, Inc. <sup>3,4</sup> ; Lilly Research Laboratories, a division of Eli Lilly and Company <sup>3,4</sup> ; Pfizer Inc. <sup>3,4</sup>	25, 56
Arthur L. Lazarus, M.D.	AstraZeneca Pharmaceuticals <sup>2,5</sup>	22
Eric J. Lenze, M.D.	Forest Pharmaceuticals, Inc. <sup>3</sup> ; Janssen Pharmaceutica Products, LP <sup>3</sup>	6
Stefan M. Leucht, M.D.	Johnson and Johnson PRD <sup>1,4</sup> ; Eli Lilly and Company <sup>4</sup> ; Sanofi-Synthelabo Pharmaceuticals, Inc. <sup>3,4</sup>	10
Alan I. Levenson, M.D.	Psychiatrists' Purchasing Group, Inc. <sup>6</sup>	19
James L. Levenson, M.D.	Eli Lilly and Company <sup>1</sup>	40, 67, 91
Frances R. Levin, M.D.	Eli Lilly and Company <sup>1</sup> ; Ortho McNeil Pharmaceutical Inc. <sup>3</sup> ; UCB Pharmaceuticals <sup>1,3</sup>	50, 81
Ronald W. Levin, M.D.	Pfizer Inc. <sup>5</sup> ; Amgen <sup>5</sup> ; Cezaene <sup>5</sup> ; Icos <sup>5</sup>	78

## DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Adele C. Viguera, M.D.	GlaxoSmithKline <sup>4</sup>	66, 99
Albert V. Vogel, M.D.	Joint Commission on Accreditation of Healthcare Organization <sup>6</sup>	72
Karen D. Wagner, M.D.	Abbott Laboratories, Inc. <sup>1,3,4</sup> ; Eli Lilly and Company <sup>1,3,4</sup> ; Forest Pharmaceuticals, Inc. <sup>1,3,4</sup> ; GlaxoSmithKline <sup>1,3,4</sup> ; Janssen Pharmaceutica Products, LP <sup>1,4</sup> ; Novartis Pharmaceuticals Corporation <sup>1,4</sup> ; Pfizer Inc. <sup>1,3,4</sup> ; Bristol-Myers Squibb <sup>1,3</sup> ; National Institute of Mental Health <sup>1,3</sup> ; Otsuka America Pharmaceutical <sup>1</sup> ; UCB Pharmaceuticals <sup>1</sup> ; Wyeth Pharmaceuticals <sup>1,3</sup> ; Organon Pharmaceuticals Inc. <sup>3</sup> ; Ortho McNeil Pharmaceutical Inc. <sup>6</sup>	4, 63
John T. Walkup, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company <sup>1,3,4</sup> ; Pfizer Inc. <sup>3,4</sup> ; Abbott Laboratories, Inc. <sup>3</sup> ; Janssen Pharmaceutica Products, LP <sup>4</sup>	42, 68, 93
B. Timothy Walsh, M.D.	Eli Lilly and Company <sup>3</sup> ; Ortho McNeil Pharmaceutical Inc. <sup>3</sup>	59, 71
G. Scott Waterman, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company <sup>3</sup> ; Bristol-Myers Squibb <sup>3</sup>	33
Peter J. Weiden, M.D.	Bristol-Myers Squibb <sup>1,3,4</sup> ; Otsuka America Pharmaceutical <sup>3</sup> ; AstraZeneca Pharmaceuticals <sup>1,3,4</sup> ; Pfizer Inc. <sup>1,3,4</sup> ; Janssen Pharmaceutica Products, LP <sup>1,3,4</sup>	51, 87
Daniel R. Weinberger, M.D.	Bristol-Myers Squibb <sup>1</sup> ; AstraZeneca Pharmaceuticals <sup>1</sup> ; Janssen Pharmaceutica Products, LP <sup>1</sup> ; Eli Lilly and Company <sup>1</sup> ; Otsuka America Pharmaceutical <sup>1</sup> ; Pfizer Inc. <sup>1</sup>	11, 52
Richard D. Weiner, M.D.	Mecta Corp. <sup>4</sup>	26
Margaret D. Weiss, M.D.	Johnson and Johnson PRD <sup>1</sup> ; Pharmacia & Upjohn Company, Inc. <sup>1</sup> ; Purdue Pharma L.P. <sup>1,3</sup> ; Eli Lilly and Company <sup>1,3,4</sup> ; Novartis Pharmaceuticals Corporation <sup>1,3,4</sup> ; Shire Ridgewood Pharmaceuticals <sup>1,3,4</sup> ; GlaxoSmithKline <sup>3</sup> ; Circa Dia <sup>3</sup>	23, 32
Steven Wengel, M.D.	Pfizer Inc. <sup>4</sup> ; Forest Pharmaceuticals, Inc. <sup>4</sup>	64
Sharon B. Wigal, Ph.D.	Alza/McNeil Pharmaceuticals <sup>1,3,4</sup> ; McNeil Consumer & Specialty Pharmaceuticals <sup>1,3,4</sup> ; Celltech Pharmaceuticals, Ltd. <sup>1,3,4</sup> ; Novartis Pharmaceuticals Corporation <sup>1,3,4</sup> ; Shire Ridgewood Pharmaceuticals <sup>1,3,4</sup> ; Celgene <sup>3,4</sup> ; Cephalon Inc. <sup>3,4</sup> ; Eli Lilly and Company <sup>3,4</sup> ; Janssen Pharmaceutica Products, LP <sup>3</sup>	62
Timothy E. Wilens, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company <sup>1,3,4</sup> ; Abbott Laboratories, Inc. <sup>1,3,4</sup> ; Alza/McNeil Pharmaceuticals <sup>1,3,4</sup> ; Celltech Pharmaceuticals, Ltd. <sup>1,3,4</sup> ; GlaxoSmithKline <sup>1,3,4</sup> ; National Institute on Drug Abuse <sup>1,3,4</sup> ; National Institute of Mental Health <sup>1,3,4</sup> ; NICMH <sup>1,3,4</sup> ; Neurosearch <sup>1,3,4</sup> ; Pfizer Inc. <sup>1,3,4</sup> ; Shire Ridgewood Pharmaceuticals <sup>1,3,4</sup>	12, 22, 62, 80
Jill Williams, M.D.	Pfizer Inc. <sup>3</sup>	26
John W. Winkelman, M.D.	Cephalon Inc. <sup>1,4</sup> ; GlaxoSmithKline <sup>1,3,4</sup> ; Pfizer Inc. <sup>1,3</sup> ; UCB Pharmaceuticals <sup>3</sup> ; Sanofi-Synthelabo Pharmaceuticals, Inc. <sup>4,1</sup> ; Eli Lilly and Company <sup>4</sup> ; Elan Pharmaceuticals <sup>1</sup> ; King Pharmaceutical <sup>1,4</sup> ; Sepracor Inc. <sup>1</sup> ; Boehringer-Ingelheim Pharmaceuticals <sup>3</sup> ; Novartis Pharmaceuticals Corporation <sup>1</sup> ; Schwarz <sup>1</sup>	9, 26, 37, 53
Katherine L. Wisner, M.D.	Pfizer Inc. <sup>4</sup> ; GlaxoSmithKline <sup>4</sup>	2, 23, 30, 41, 58
Madelaine M. Wohlreich, M.D.	Eli Lilly and Company <sup>2</sup>	90
William C. Wood, M.D.	Aventis <sup>1</sup> ; Genomic Health <sup>1</sup>	49
Scott W. Woods, M.D.	Bristol-Myers Squibb <sup>3</sup> ; UCB Pharmaceuticals <sup>3</sup>	30
Janet Wozniak, M.D.	Janssen Pharmaceutica Products, LP <sup>4</sup> ; Eli Lilly and Company <sup>3,4</sup> ; Shire Ridgewood Pharmaceuticals <sup>1</sup>	35
Jesse H. Wright, M.D.	Mindstreet <sup>5,6</sup> ; Eli Lilly and Company <sup>6</sup>	8, 26, 50
Joel Yager, M.D.	Ortho McNeil Pharmaceutical Inc. <sup>1</sup> ; Janssen Pharmaceutica Products, LP <sup>6</sup>	1, 6, 17, 25, 45, 68, 83, 97
Kimberly A. Yonkers, M.D.	Berlex Laboratories, Inc. <sup>1,3</sup> ; GlaxoSmithKline <sup>1,3</sup> ; Wyeth Pharmaceuticals <sup>1</sup> ; Pfizer Inc. <sup>1</sup> ; National Institute on Drug Abuse <sup>3</sup> ; National Institute of Mental Health <sup>3</sup> ; HRSA <sup>3</sup>	13, 30
Mary Zanarini, Ed.D.	Eli Lilly and Company <sup>1,3</sup>	7
Phyllis C. Zee, M.D.	Sanofi-Synthelabo Pharmaceuticals, Inc. <sup>4</sup> ; Takeda Pharmaceuticals <sup>1,3</sup>	9, 53
Douglas M. Ziedonis, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company <sup>1,3,4</sup> ; Janssen Pharmaceutica Products, LP <sup>1,3,4</sup> ; Bristol-Myers Squibb <sup>1,3,4</sup>	26
Robert B. Zipursky, M.D.	Eli Lilly and Company <sup>3,4</sup> ; Novartis Pharmaceuticals Corporation <sup>4,3</sup> ; AstraZeneca Pharmaceuticals <sup>3,4</sup> ; Pfizer Inc. <sup>5</sup>	10, 12
Sidney Zisook, M.D.	GlaxoSmithKline <sup>1,4</sup> ; AstraZeneca Pharmaceuticals <sup>4</sup> ; Janssen Pharmaceutica Products, LP <sup>4</sup> ; Pfizer Inc. <sup>4</sup> ; Eli Lilly and Company <sup>4</sup> ; Wyeth Pharmaceuticals <sup>4</sup> ; Forest Pharmaceuticals, Inc. <sup>4</sup>	31, 82
Joseph Zohar, M.D.	Solvay Pharmaceuticals, Inc. <sup>3</sup> ; Eli Lilly and Company <sup>3</sup>	79